Joleen M Hubbard
Overview
Explore the profile of Joleen M Hubbard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
1124
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ahn D, Ridinger M, Cannon T, Mendelsohn L, Starr J, Hubbard J, et al.
J Clin Oncol
. 2024 Oct;
43(7):840-851.
PMID: 39475591
Purpose: This phase II study evaluated the efficacy and tolerability of onvansertib, a polo-like kinase 1 (PLK1) inhibitor, in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI) + bevacizumab for the...
2.
Tevaarwerk A, Karam D, Gatten C, Harlos E, Maurer M, Giridhar K, et al.
Cancer
. 2024 Apr;
131(1):e35304.
PMID: 38662502
Introduction: Structured data capture requires defined languages such as minimal Common Oncology Data Elements (mCODE). This pilot assessed the feasibility of capturing 5 mCODE categories (stage, disease status, performance status...
3.
Emiloju O, Yin J, Koubek E, Reid J, Borad M, Lou Y, et al.
Invest New Drugs
. 2024 Jan;
42(1):127-135.
PMID: 38270822
Navitoclax (ABT-263) is an oral BCL2 homology-3 mimetic that binds with high affinity to pro-survival BCL2 proteins, resulting in apoptosis. Sorafenib, an oral multi kinase inhibitor also promotes apoptosis and...
4.
Zhu M, Taylor W, Mahoney D, Then S, Berger C, Burger K, et al.
Cancers (Basel)
. 2023 Dec;
15(24).
PMID: 38136324
Background: Radiographic surveillance of colorectal cancer (CRC) after curative-intent therapy is costly and unreliable. Methylated DNA markers (MDMs) detected primary CRC and metastatic recurrence with high sensitivity and specificity in...
5.
Saberzadeh-Ardestani B, Jones J, McWilliams R, Tougeron D, Halfdanarson T, Guimbaud R, et al.
Eur J Cancer
. 2023 Nov;
196:113433.
PMID: 37979306
Purpose: Only one-half of deficient mismatch repair (d-MMR) metastatic colorectal cancers (mCRC) demonstrate durable responses to immune checkpoint inhibitors (ICIs). Given preclinical data indicating that liver metastases sequester activated CD8...
6.
Emiloju O, Zhu M, Xie H, Jin Z, Sinicrope F, Hubbard J
Curr Treat Options Oncol
. 2023 Nov;
24(12):1739-1757.
PMID: 37966682
Standard frontline treatment of metastatic colorectal cancer (CRC) is cytotoxic chemotherapy plus a biologic agent such as an anti-EGFR monoclonal antibody (cetuximab or panitumumab) or anti-VEGF antibody (bevacizumab). Predictive biomarkers...
7.
Ou F, Ahn D, Dixon J, Grothey A, Lou Y, Kasi P, et al.
Cancers (Basel)
. 2023 Aug;
15(16).
PMID: 37627145
Patients And Methods: Patients enrolled in 17 first-line clinical trials, who had mCRC with ≥ 2 lesions at baseline, and a restaging scan by 12 weeks were included. For each...
8.
Storandt M, Rogen K, Iyyangar A, Schnell R, Mitchell J, Hubbard J, et al.
Cancers (Basel)
. 2023 Jul;
15(14).
PMID: 37509234
Over the past 20 years, rates of early-onset colorectal cancer (eoCRC), defined as <50 years of age at diagnosis, have increased, with 16-25% associated with a pathogenic germline variant (PGV)...
9.
Meng L, Thapa R, Delgado M, Gomez M, Ji R, Knepper T, et al.
JAMA Netw Open
. 2023 Jun;
6(6):e2320035.
PMID: 37358854
Importance: While the incidence of early-onset metastatic colorectal cancer (mCRC) has been increasing, studies on the age-related disparity in this group of patients are limited. Objective: To evaluate the association...
10.
Snyder R, Dueck A, Fruth B, Shi Q, Hubbard J, Herman J, et al.
Ann Surg
. 2023 Jun;
278(4):598-608.
PMID: 37334719
Objective: We sought to evaluate symptomatic adverse event (AE) rates among patients with pancreatic cancer receiving neoadjuvant therapy on clinical trial (A021501) using the Patient-Reported Outcomes Common Terminology Criteria for...